Table 2.
Summary of measurements and study outcomes
| Measurements | Instruments | Group | T0 | T1 | T2 | Outcome | |
|---|---|---|---|---|---|---|---|
| Surveys/measuring tools |
|
|
|||||
| Socio-demographic and lifestyle |
Questionnaire |
ICG, UCG |
x |
|
|
|
2˚ |
| Health-related quality of life I,E |
WHO-5 Well-being index (1998) |
ICG, UCG |
x |
|
x |
1˚ |
|
| Sleep scale scores I,E |
ESS, ISI, MAPI, IRLSSG |
ICG, UCG |
x |
|
x |
1˚ |
|
| Community pharmacy survey I |
Questionnaire |
ICG, UCG |
x |
|
|
|
2˚ |
| Close-out survey E |
Questionnaire |
ICG, UCG |
|
|
x |
1˚ |
2˚ |
| Sleep parameters assessment |
|
|
|||||
| SE% |
Actigraph only |
ICG |
|
x |
x |
1˚ |
|
| TST, NWAK, SOL |
Actigraph and sleep |
ICG |
|
x |
x |
1˚ |
|
| |
diary |
|
|
|
|
|
|
| Other factors that may interrupt sleep |
Sleep diary only |
ICG |
|
x |
x |
1˚ |
|
| Pharmacy survey |
|
|
|||||
| Close-out survey for pharmacy | Questionnaire | Pharmacists, pharmacy staff | x | 2˚ | |||
T0 = baseline, T1 = 1 week after baseline, T2 = 2 weeks after baseline.
ICG: intervention care group; UCG: usual care group.
ESS: Epworth Sleepiness Scale; ISI: Insomnia Severity Index; MAPI: Multivariate Apnea Prediction Index; IRLSSG: International Restless Legs Syndrome Study Group.
SE%: Percentage of sleep efficiency; TST: Total sleep time per-24 hour period; NWAK: Number of nocturnal awakenings; SOL: Sleep onset latency.
1˚: Primary outcome; 2˚: Secondary outcome.
I: ‘Initial Pharmacy Visit’ Questionnaires; E: ‘End of Study’ Questionnaires.